Welcome to Rinri

Founded in 2018, Rinri Therapeutics Ltd. is a therapeutic discovery and development company working in the field of hearing loss supported by Boehringer Ingelheim Venture Fund and UCB Ventures, BioCity and The University of Sheffield.

Rinri Therapeutics has been founded on pioneering research into regenerative cell therapy for hearing loss, led by Professor Marcelo Rivolta at the University of Sheffield.

The Company has a team of experienced management, strong academic pedigree and excellent potential for clinical development.

Hearing Loss

Our Technology

Rinri’s lead therapeutic candidate is Rincell-1. It is a novel progenitor cell product and a first-in-class regenerative cell therapy. Rincell-1 seeks to regenerate auditory neurones and re-establish the transmission of nerve signals from the inner ear to the auditory centres of the brain, to reverse hearing loss in individuals with age-related hearing loss or Auditory Neuropathy.

Our Technology

Rinri’s lead therapeutic candidate is Rincell-1. It is a novel progenitor cell product and a first-in-class regenerative cell therapy. Rincell-1 seeks to regenerate auditory neurones and re-establish the transmission of nerve signals from the inner ear to the auditory centres of the brain, to reverse hearing loss in individuals with age-related hearing loss or Auditory Neuropathy.

Media

Our latest press releases

Our Therapy Area

People living with sensorineural hearing loss, and their families, are at the heart of our work here at Rinri. We are developing an innovative and life-changing cell therapy, and bringing it from the laboratory to patients, to address a large and unmet clinical need.

Our Team